Interview With Joshua White

In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..

So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

Excitingly, Mindset is moving towards beginning clinical trials in 2022.

On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

In the long term, this deal has great potential for Otsuka. 

To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

Can psychedelics treat mental illnesses such as depression?

Are next-generation psychedelics better than the originals?

What is happening in the brain when a person takes psychedelics?

Enjoy the episode!

You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

#MindsetPharma #DMT #microdosing

Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.

The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).

Hope you guys enjoy this video!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #mmed #mindmedstock
Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU